Abstract 1120
Background
Brigatinib is a next-generation ALK inhibitor with activity against a broad range of ALK mutations and ROS1 rearrangements. It is approved for use post-crizotinib in ALK+ mNSCLC based on phase II trial (ALTA) data, and significantly improved progression-free survival (PFS) vs crizotinib (HR = 0.49) in ALK TKI-naïve patients (pts) in the phase III ALTA-1L trial. UVEA-Brig captures detailed information about brigatinib therapy in a real-world situation.
Methods
UVEA-Brig is a retrospective analysis of data from pts who started brigatinib between 06/16 and 12/17 in Italy, Norway, Spain and the UK in an expanded access program (EAP). Due to legislation in Italy, only data for deceased pts and pts who had been followed up for 18 months could be used. Adults with mNSCLC, including those with brain lesions, who are resistant to or intolerant of at least one prior ALK inhibitor and have ECOG performance status ≤3 are eligible. The primary objective is to describe baseline characteristics, prior therapy, clinical outcomes and safety with brigatinib.
Results
Data for 50 pts are available (male: 40%; never smoker: 54%; adenocarcinoma: 94%: stage IV at diagnosis: 92%; median age: 51 [31–78] years; brain lesions at study entry: 60% [46% irradiated]). Median follow-up 6 (range 0–24) months. Pts had received a median of 2 (range 1–6) lines of prior systemic therapy (≥3 lines: 34%), with a median of 1 (1–5) prior ALK TKI (crizotinib 84%; ceritinib 46%; alectinib 10%; lorlatinib 8%). 36 pts have discontinued brigatinib (progression: 25; adverse events: 3 [pneumonitis, amylase and creatine kinase increase, and asthenia/fatigue]). 43 pts were evaluable for best response: complete response: 1 (2.3%); partial response: 14 (32.6%); stable disease: 20 (46.5%) (response rate: 34.9%; disease control rate: 81.4%). Median response duration was 9.7 (range 0.7–23.4) months. Median PFS was 5.7 (95% CI 6.2–9.9) months; median OS was 10.2 (8.6–12.6) months. 20 pts received subsequent therapies; 17 had an ALK inhibitor, most commonly lorlatinib (n = 10).
Conclusions
These data from daily clinical practice support the activity of brigatinib also in pts with heavily pretreated ALK+ mNSCLC.
Clinical trial identification
Editorial acknowledgement
Andrew Noble, Bioscript Group.
Legal entity responsible for the study
Takeda.
Funding
Takeda.
Disclosure
S. Novello: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda, BMS, Moehringer Ingelheim, Eli Lilly, Celgene, Pfizer, Roche, AstraZeneca, MSD, AbbVie. O.T. Brustugun: Honoraria (institution): Takeda. J. Cadranel: Advisory / Consultancy: Takeda; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Roche. F. Griesinger: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Takeda; Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Siemens; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ariad; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie. M.J. Hochmair: Honoraria (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self): Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Takeda; Advisory / Consultancy: Novartis. M. Pérol: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda. S. Popat: Honoraria (self), Research grant / Funding (institution): BMS, Roche, Takeda, Pfizer, MSD, EMD Serono, Boehringer Ingelheim; Honoraria (self): Chugai, Novartis, Guardant Health, AbbVie, Medscape, Tesaro, OncLive, AstraZeneca; Research grant / Funding (institution): Bayer, Celgene, Synta, Clovis Oncology, Eli Lilly, Epizyne, Ariad; Research grant / Funding (self): Elsevier. N. Bent-Ennakhil: Full / Part-time employment: Takeda. C. Kruhl: Full / Part-time employment: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract